Overview
Bioavailability Study for New Atorvastatin Formulation
Status:
Completed
Completed
Trial end date:
2008-03-01
2008-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision making on formulation development.Phase:
Phase 4Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Treatments:
Atorvastatin
Atorvastatin Calcium
Criteria
Inclusion Criteria:- Healthy male and/or female subjects
- Body Mass Index (BMI) of approximately 18 to 30 kg/m2
Exclusion Criteria:
- Any condition possibly affecting drug absorption
- A positive urine drug screening